Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Pay changes to combat rising prices in Medicare’s multibillion-dollar office-administered drug benefit got strong support from a panel of congressional advisers.
The draft package crafted and debated by the Medicare Payment Advisory Commission March 2 tries to chop payments for Part B drugs on a variety of fronts. Examples include cuts to add-on payments for pharmaceuticals, and requirements for drugmakers to pay rebates when the prices of their products exceed a certain level.
Medicare pays doctors for these treatments based on manufacturers’ average sales price plus 6 percent, known as ASP + 6 percent.
An overhaul is needed because spending on drugs that are injected or otherwise given in medical offices and outpatient departments grew to $26 billion in 2015, $3 billion more than in 2014, MedPAC said. It’s believed that the “buy and bill” payment system with its add-on provides incentives to use higher-priced pharmaceuticals.
The MedPAC commissioners will vote in April on whether, and in what form, to send the recommendations to Congress in June.
A centerpiece of the recommendations is the creation of a voluntary market-based program in which private vendors would negotiate prices with manufacturers on behalf of medical providers. Providers would enroll, rather than purchasing the products from a distributor.
The Drug Value Program would start in 2022 with a small number of private vendors. Medicare would reimburse the doctors based on the negotiated price and the vendors would, in turn, receive an administrative fee. They also would have opportunities for shared savings.
After the program was up and running, the 6 percent add-on would be reduced to encourage doctors to enroll.
The vendor program isn’t the first time Medicare has tried this approach.
A previous incarnation, known as the competitive acquisition program, experienced low enrollment and died in 2008.
The proposed program is intended to offer vendors more bargaining leverage. They can use a formulary, for example, unlike under the previous program in which all drugs had to be offered.
The formulary is expected to spur price competition among products with therapeutic alternatives, Kim Neuman, a MedPAC analyst, said at the March 2 meeting.
In the meantime, the commissioners want Congress and the Department of Health and Human Services in 2018 to undertake other changes, including requiring penalties for drugmakers that fail to report ASP data.
Another recommendation would be for Congress to cut in half—from 6 percent to 3 percent—the add-on payment for new single-source drugs and biosimilars that are reimbursed at the wholesale acquisition cost.
Under another proposal, manufacturers would have to pay Medicare a rebate when the ASP for their product exceeds an inflation benchmark. “Savings from rebates would be shared with beneficiaries by basing cost-sharing on the lower inflation-adjusted average sales price,” Nancy Ray, a MedPAC analyst, said at the meeting.
In addition, the Medicare agency would be required to use a common billing code to pay for a reference biologic (the branded drug) and its biosimilars.
Currently, “we do not have maximum competition for single-source drugs and reference biologics because they are each paid under their own billing codes,” Ray said. Medicare should pay similar rates for similar care, she said. That way, doctors would be more likely to choose the most appropriate product.
“I fully support the recommendations,” Commissioner Craig Samitt, an executive vice president and chief clinical officer at Anthem Inc., said. “In fact, I don’t think they go far enough” toward reining in unsustainable increases in drug costs.
“We should go ahead and see what happens, assuming Congress wants to follow up on this fine advice,” Commissioner Jack Hoadley, a research professor at Georgetown University, said.
However, it’s unclear whether Congress and the administration would consider the recommendations.
A series of suggested changes to the Part D drug benefit in 2016 has yet to be considered.
Not surprisingly, drug manufacturers and oncology practices objected to the draft recommendations.
“Proposed changes to Medicare Part B could have a detrimental impact on access for patients who rely on Part B therapies,” Allyson Funk, senior director, public affairs, Pharmaceutical Research and Manufacturers of America, told Bloomberg BNA.
“The current Medicare Part B payment methodology is an effective, market-based pricing mechanism that successfully balances patient access with controlling costs,” she said.
Ted Okon, executive director of the Community Oncology Alliance, called the focus on Part B reimbursement “misguided and disconcerting.”
“MedPAC is proposing changes that will accelerate the shift of care from physicians’ offices to hospitals,” he told Bloomberg BNA. “That’s because MedPAC doesn’t understand the fragile nature of the current Part B system for physicians and, especially in oncology, the huge profit motivations for hospitals to acquire physician-owned practices.”
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)